Leman Biotech

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Leman Biotech, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Leman Biotech please access flcube.comFineline Info & Tech (Flcube.com) provides you with comprehensive information about Leman Biotech, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare.

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery
CompanyDeals

Atavistik Bio Strikes CVRM Collaboration with Roche – USD 70 Million Upfront, up to USD 1.9 Billion in Milestones for Allosteric Small‑Molecule Discovery

Atavistik Bio announced a strategic research collaboration with Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) to discover and develop novel small molecule therapies targeting multiple targets in cardiovascular, renal, and…

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billio

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billion

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T
CompanyDeals

Leman Biotech Raises RMB 200M Series A+ – Advances Ultra‑Low‑Dose Metabolically Armored CAR‑T

Leman Biotech Advances Automated CAR-T Production with Zhongshan Life Science Park Move
Company

Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation

Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies
CompanyDeals

Leman Biotech Secures Over USD 13.9 Million in Series A Financing for Next-Gen Cancer Immunotherapies

CompanyDeals

Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy